Evidence map›Paper›PMID 39913302›Full record

ReviewMolecular biology of the cell2025

When everything is a master regulator, nothing is.

Robert S Krauss, Michael Kyba

Abstract readReview
In one paragraph

Review in Molecular biology of the cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Robert S KraussDepartment of Cell, Developmental, and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Michael KybaLillehei Heart Institute and Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455.

Funding

Probing the Activity of DUX4 in FSHDR01AR055685 · NIAMS · UNIVERSITY OF MINNESOTA · PI Michael Kyba · 2010 to 2026
$7.0M
Molecular and Developmental Analysis of HoloprosencephalyR01DE024748 · NIDCR · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Robert S. Krauss · 2015 to 2026
$5.2M
Cadherin-Dependent Regulation of Satellite Cell FunctionR01AR070231 · NIAMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAUSS, ROBERT S. · 2016 to 2025
$4.9M
Regulation of Muscle Stem Cells by Netrin SignalingR21AR084632 · NIAMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAUSS, ROBERT S. · 2024 to 2025
$403k
NIAMS NIH HHS R01 AR055685NIAMS NIH HHS R01 AR070231NIAMS NIH HHS R21 AR084632NIDCR NIH HHS R01 DE024748
6 · The paper itself

Abstract

The term "master regulator" emerged in the 1960s and 1970s and referred to autoregulatory transcription factors that sat atop a developmental lineage. Since that time, usage of the term has increased and broadened to the point where it has lost clear meaning. Here we discuss the term "master regulator" with the goals of developing a consensus view of its definition and stimulating discussion on use of similar terms. We propose that the designation "master regulator" be reserved for transcription factors that are: 1) positioned at the top of a regulatory hierarchy specifying a cell lineage (and potentially specific cell states, such as hypoxia); and 2) sufficient to drive the transcriptional program characterizing that lineage or state. It is hoped that this piece will provide a precedent for use of additional terms applied to incompletely understood biological processes, resulting in experimentation that sheds light on such processes.

Indexed as

Transcription FactorsAnimalsCell LineageHumansTranscription, GeneticTranscription Factors

Identifiers

PMID39913302
PMCPMC11974949

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.